Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptus PharmaBOM:544529 +3.63%18 Days Payable is 82.64 as of Mar. 2026, which is 43% above its 10-year median of 57.92. GuruFocus rates BOM:544529 with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 117 Medical Distribution companies, Aptus Pharma ranks better than 56.41% on this metric.
The historical rank and industry rank for Aptus Pharma's Days Payable or its related term are showing as below:
BOM:544529'
s Days Payable Range Over the Past 10 Years
Min: 51.88 Med: 57.92 Max: 87.63
Current: 87.63
During the past 4 years, Aptus Pharma's highest Days Payable was 87.63. The lowest was 51.88. And the median was 57.92.
BOM:544529's Days Payable is ranked better than 56.41% of 117
companies
in the Medical Distribution industry
Industry Median: 79.11
vs BOM:544529: 87.63
Aptus Pharma's Days Payable
increased
from Mar. 2025 (44.73) to Mar. 2026 (82.64).
It may suggest that Aptus Pharmadelayed paying its suppliers.
The historical data trend for Aptus Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544529 vs MCK, COR, CAH: Days Payable Comparison
For the Medical Distribution subindustry, Aptus Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptus Pharma Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Aptus Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Aptus Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aptus Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptus Pharma (BOM:544529) has a Days Payable of 82.64 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aptus Pharma and its competitors. This is 43% above median its historical median of 57.92. Over the past decade, Aptus Pharma's Days Payable has ranged from 51.88 to 87.63. According to the industry distribution chart, Aptus Pharma ranks #51 out of 117 companies in the Medical Distribution industry, placing it in the top 43.6%.
Is Aptus Pharma's Days Payable too high?
Aptus Pharma's current Days Payable of 82.64 is 43% above median its 10-year median of 57.92. Over the past 10 years, this metric has ranged from a low of 51.88 to a high of 87.63. The Medical Distribution industry median Days Payable is 79.11. Aptus Pharma's value of 82.64 is 4.5% above this industry median. Based on the distribution chart, Aptus Pharma ranks #51 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Aptus Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Aptus Pharma's Days Payable compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Aptus Pharma ranks #51 out of 117 companies for Days Payable. This puts Aptus Pharma in the upper half of its industry. The industry median Days Payable is 79.11. Aptus Pharma's value of 82.64 is 4.5% above this benchmark. Historically, Aptus Pharma's own Days Payable has ranged from 51.88 to 87.63 over the past decade. While the company's 10-year median is 57.92 vs. the industry median of 79.11, Aptus Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.11, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptus Pharma's current Days Payable of 82.64 is 4.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aptus Pharma and its competitors. For the Medical Distribution industry, the median Days Payable is 79.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptus Pharma's current Days Payable is 82.64, which is 43% above median its own 10-year median of 57.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptus Pharma stock overvalued right now?
Aptus Pharma (BOM:544529) has a current Days Payable of 82.64. The current Days Payable is 82.64, which is 43% above median its 10-year median of 57.92 and 4.5% above the Medical Distribution industry median of 79.11. Aptus Pharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aptus Pharma (BOM:544529), the current Days Payable is 82.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. The group provides a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
18GF Score
Get the complete analysis for BOM:544529
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544529 has been successfully added to your 
